 Lexaria Bioscience Corp NASDAQ: LEXX is trading higher Tuesday after the company announced initial results from its human clinical study of DehydraTECH, saying the study evidences up to 23 decrease in blood pressure with DehydraTECH-CBD relative to placebo. Lexaria Bioscience noted that additional blood pressure subset analyses, sleep quality and all other data analyses are in progress and will be reported when complete. 